β3 adrenergic receptor as potential therapeutic target in ADPKD-Reference-Cited by-同舟云学术

β3 adrenergic receptor as potential therapeutic target in ADPKD

Published:2021-10 Issue:20 Volume:9 Page:
ISSN:2051-817X
Container-title:Physiological Reports
language:en
Short-container-title:Physiol Rep

Author:

Schena Giorgia¹^ORCID,Carmosino Monica¹²^ORCID,Chiurlia Samantha³,Onuchic Laura¹,Mastropasqua Mauro⁴^ORCID,Maiorano Eugenio⁴^ORCID,Schena Francesco P.³⁵^ORCID,Caplan Michael J.¹^ORCID

Affiliation:

1. Department of Cellular and Molecular Physiology Yale University School of Medicine New Haven Connecticut USA

2. Department of Sciences University of Basilicata Potenza Italy

3. Schena Foundation Valenzano Italy

4. Department of Emergency and Organ Transplantation Section of Pathological Anatomy University of Bari Bari Italy

5. Department of Emergency and Organ Transplantation Section of Nephrology University of Bari Bari Italy

Funder

National Institutes of Health

Publisher

Wiley

Subject

Physiology (medical),Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.14814/phy2.15058

Reference20 articles.

1. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells11See Editorial by Torres, p. 1283.

2. Immunofluorescent imaging of β1- and β2-adrenergic receptors in rat kidney

3. β3-adrenoreceptor blockade reduces tumor growth and increases neuronal differentiation in neuroblastoma via SK2/S1P2 modulation

4. Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progression

5. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-Species Insights into Autosomal Dominant Polycystic Kidney Disease: Provide an Alternative View on Research Advancement;International Journal of Molecular Sciences;2024-05-22

2. Mirabegron, dependent on β3-adrenergic receptor, alleviates mercuric chloride-induced kidney injury by reversing the impact on the inflammatory network, M1/M2 macrophages, and claudin-2;International Immunopharmacology;2024-01

3. Patent highlights February–March 2023;Pharmaceutical Patent Analyst;2023-11-20

4. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon;Advances in Kidney Disease and Health;2023-05

5. The β3 adrenoceptor in proliferative retinopathies: “Cinderella” steps out of its family shadow;Pharmacological Research;2023-04